血清CA125在卵巢癌早期诊断中的临床应用价值

目的探讨血清CA125浓度检测对卵巢癌早期诊断的临床应用价值。方法运用化疗发光免疫法对卵巢癌患者及卵巢良性肿瘤患者血清CA125浓缩的检测,同时选取健康体检人群作为对照组。结果卵巢癌患者组血清CA125浓度明显高于卵巢良性肿瘤患者组和正常对照组,差异有统计学意义（P〈0.01）。结论血清CA125对卵巢癌的早期诊断有重要价值。     

癌相关糖抗原125在女性生殖系统肿瘤诊断中的应用

目的　探讨癌相关糖抗原 12 5 (CA12 5 )在女性生殖系统肿瘤诊断的应用价值。方法　应用酶联免疫吸附(EL ISA)试验定量测定了 5 5 8例妇科住院患者和 92例健康妇女血清中 CA12 5的含量。结果　卵巢恶性肿瘤组、非卵巢妇科恶性肿瘤组、卵巢良性肿瘤组、子宫良性肿瘤组以及妇科良性疾病组 CA12 5分别为 45 4.0 U/ ml± 5 0 7.4U/ ml,15 9.3U / ml± 336 .9U/ ml,5 2 .9U / ml± 139.2 U / ml和 36 .9U/ ml± 75 .7U / ml,与健康对照组比较 ,除妇科良性疾病组无显著差异外 (P>0 .0 5 ) ,其余各组差异均有显著意义 (P<0 .0 5 ) ;卵巢恶性肿瘤组与各组比较有极显著差异 (P<0 .0 1)。CA12 5在诊断卵巢恶性肿瘤的阳性检出率远高于其余各组 ,敏感性、特异性和有效性分别为 87.5 %、79.3%、77.7%。结论　 CA12 5动态测定对卵巢癌的早期诊断、疗效观察及预测复发等有一定临床意义     

血清CA125检测对肿瘤诊断价值的探讨

目的检测血清中CA125含量,探讨其在肿瘤疾病诊断中的应用价值。方法应用ELISA方法分别检测150例肿瘤患者(38例卵巢癌,22例其他癌,即肝癌、肺癌和胃癌,50例卵巢囊肿,40例子宫肌瘤)和正常对照组40例血清CA125含量。结果卵巢癌、其他癌(肝癌、肺癌和胃癌)、卵巢囊肿和子宫肌瘤患者CA125阳性率分别为78.9%、45.5%、16.0%和2.5%;CA125含量分别为(217.9±225.2)U/ml、(105.8±55.0)U/ml、(67.3±34.7)U/ml和(17.0±7.1)U/ml,正常对照组为(13.4±7.4)U/ml。结论(1)恶性肿瘤患者比良性肿瘤患者CA125阳性率高,均值比较呈显著性差异(t=2.171,P<0.05);(2)妇科恶性肿瘤患者比其他恶性肿瘤患者(肝癌、肺癌和胃癌)CA125阳性率高,均值比较差异不显著(t=1.570,P>0.05);(3)良性肿瘤患者中卵巢囊肿CA125均值与正常对照组比较,有极显著性差异(t=9.281,P<0.001),而子宫肌瘤患者与正常对照组比较则无显著性差异(t=1.170,P>0.05)。CA125检测对妇科肿瘤疾病的诊断价值最大,对肝癌、肺癌和胃癌的诊断有一定参考价值,对良性肿瘤诊断价值有限。     

不同病理特点的卵巢癌外周血癌胚抗原-125表达变化观察

目的 观察不同病理特点的卵巢癌患者外周血癌胚抗原(CA)-125表达变化.方法 连续选择近期接受手术治疗的卵巢癌患者74例,治疗前进行外周血CA-125标本采集,并根据手术切除标本的病理特点进行分组,比较CA-125浓度值和阳性率分布情况.结果 具有中、低程度分化、Ⅲ和Ⅳ期组、淋巴结转移和瘤体≥5 cm病理特点的卵巢癌患者CA-125浓度值和阳性例数均明显高于高分化、浸润外膜无淋巴结转移和瘤体<5 cm患者(P均<0.05～0.01).结论 卵巢癌细胞分化程度、瘤体大小、FIGO临床分期及有无淋巴结转移等病理特征明确影响着患者外周血CA-125表达和阳性率情况.     

卵巢癌患者血清CA125、HE4和OPN的表达及意义

[目的]探讨卵巢癌患者血清糖类抗原125 (CA125)、骨桥蛋白(OPN)、人附睾分泌蛋白4(HE4)的表达及意义.[方法]选择2010年6月至2012年7月本院妇科收治的卵巢癌患者35例(A组)、卵巢良性肿瘤患者73例(B组)及40例同期体检的健康妇女(C组)为研究对象,应用电化学发光法检测三组患者手术前后血清CA125水平,ELISA法检测患者手术前后血清HE4、OPN水平,比较三种肿瘤标志物单项及联合检测在卵巢癌诊断中的特异性及敏感性.[结果]A组术前血清CA125、HE4和OPN水平分别为(98.64±220.91)U/mL、(412.3±278.62) pmol/mL和(94.6±61.06) ng/mL,与B组、C组比较差异均有统计学意义(P＜0.05);A组手术前血清CA125、HE4和OPN水平与术后1个月比较,差异均有统计学意义(P＜0.05).联合检测诊断卵巢癌的特异性(78.1％)稍低于血清CA125、HE4和OPN单项指标检测(80.8％、100％、87.6％),但比较差异无统计学意义(P＞0.05),而血清联合检测诊断卵巢癌的敏感性(94.3％)显著高于血清CA125、HE4和OPN单项指标检测(77.1％、71.4％、37.1％),其差异有统计学意义(P＜0.05).[结论]联合检测卵巢癌患者血清CA125、HE4和OPN水平可作为诊断和评估卵巢癌预后的参考指标.     

卵巢癌患者80例CA125水平的回顾性分析

本文通过检测患者血清中CA125的含量，对临床资料进行回顾性分析，探讨血清CA125水平对卵巢癌诊断、治疗、复发的预测价值。     

血清糖链抗原125在上皮性卵巢癌诊断和评估预后中的意义

近年来,上皮性卵巢癌(EOC)的发病率较为稳定,患者的生存率有所提高,5年生存率达45.9%。EOC患者生存率的提高,可归结为手术的管理、有效的细胞毒性药物开发和腹腔给药化疗的进步。通过筛查和早期检测,EOC患者的生存率可得到改善,但截至目前尚未建立有效的筛查方法。糖     

癌相关抗原125在恶性卵巢肿瘤治疗前后的变化

目的 对卵巢癌相关抗原125（CA125）在恶性卵巢肿瘤治疗前后进行不同时间段的动态监测，并探讨其临床应用价值。方法 采用电化学发光免疫分析法测定恶性卵巢肿瘤患者不同时间段的血清（或血浆）CA125值，观测其在恶性卵巢肿瘤患者治疗前后的变化。结果 在恶性卵巢肿瘤患者治疗中，术前及术后等5个不同时间段CA125的检测结果显示，术前与术后有明显差异，测定结果的均值由术前的197．2U／ml降低为术后1年的24．8U／ml；术前数据范围为10～1129U／ml、检出阳性率80．7％，术后1年数据范围降低为7．0～79．9U／ml、检出阳性率19．2％。结论 CA125的动态监测在恶性卵巢肿瘤患者治疗中有较好的临床应用价值。     

血清CA-125对卵巢癌的早期诊断及预后预测

1．1 对象 我院2002-01～2004-05妇科门诊、病房及内科病房患118例。其中卵巢癌60例．卵巢良性肿瘤26例(其中伴腹水7例)，子宫内膜异位症18例，腹腔结核(有腹水)6例，肝硬化腹水5例，其他不明原因腹水3例。     

血清CA125在卵巢癌诊断及预测分期中的应用价值

目的探讨血清CA125在卵巢癌诊断及预测分期中的应用价值。方法我院妇产科2001年1月—2010年10月收治卵巢癌病人520例,测定其血清CA125水平,并分析其与卵巢癌病理组织学类型、临床分期的关系。结果 520例卵巢癌病人中上皮性卵巢癌组血清CA125水平与生殖细胞肿瘤组及性索间质肿瘤组比较明显增高（F=9.466,P〈0.01）;上皮性卵巢癌组中浆液性囊腺癌CA125水平与黏液性腺癌及透明细胞癌相比明显增高（F=7.399,P〈0.01）;Ⅲ～Ⅳ期组CA125的水平明显高于Ⅰ～Ⅱ期组（F=54.720,t=7.852,P〈0.01）;低分化组血清CA125水平明显高于高、中分化组（F=47.031,t=6.880,P〈0.01）;血清CA125含量〉46.36kU/L时,上皮性卵巢癌的诊断价值最高,对应的诊断灵敏度为82.6%,特异度为61.8%;当CA125〉150kU/L时,晚期病人诊断灵敏度、特异度及准确率分别为85.66%、59.22%及75.48%,此时对卵巢癌晚期诊断意义大。结论血清CA125对上皮性卵巢癌的诊断具有较高价值,尤其是上皮性浆液性囊腺癌病人血清CA125水平升高明显;晚期（Ⅲ～Ⅳ期）以及低分化病人CA125水平较高;CA125诊断价值的最佳临界点高于普遍认为的阳性诊断标准,当CA125〉150kU/L时,对晚期病人诊断意义较大。     

Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions

Carbohydrate antigen-125 (CA-125) is a tumor marker that has been used for differential diagnosis of peritoneal malignancies. The aim of the present study was to evaluate the diagnostic usefulness of simultaneous quantification of CA-125 in peritoneal fluid and serum for abdominal cancer cases and noncancer diseases. Noncancer disease group included cirrhotic patients (n=28) and spontaneous bacterial peritonitis (SBP) patients (n=11). Abdominal cancer group was composed of histologically diagnosed various malignancies (n=10), such as gastric cancer. CA-125 levels were quantified by chemiluminescent enzyme immuno-assay. Diagnostic usefulness tests and receiver operating characteristics (ROC) curve analysis were performed for the levels of peritoneal fluid CA-125 (pCA-125) and serum CA-125 (sCA-125), and the ratio of pCA-125 to sCA-125 (p/sCA-125). The sCA-125 levels were significantly higher in noncancer patients than those in the cancer patients, while the pCA-125 levels showed no significant difference between the two groups. Notably, the p/sCA-125 ratio was significantly lower in the noncancer patients than that in the cancer patients. Area under the ROC curve was 0.267 for sCA-125, 0.542 for pCA-125 and 0.831 for p/sCA-125. The accepted cutoff values were the combination of values that gave the greatest diagnostic sensitivity plus specificity. Either sCA-125 or pCA-125 value gave lower diagnostic accuracy, whereas p/sCA-125 value demonstrated a significantly higher diagnostic accuracy (sensitivity-specificity pairs: 0.40-0.33 for sCA-125, 0.60-0.54 for pCA-125, and 0.80-0.72 for p/sCA-125, respectively). Hence, determination of p/sCA-125 improves the biochemical discrimination of abdominal cancerous cases from noncancerous diseases.     

血清细胞角蛋白19片段抗原、糖类抗原125和50水平在肺癌中的诊断价值

目的探讨血清细胞角蛋白19片段抗原(CYFRA21-1)、糖类抗原125(CA125)和糖类抗原50(CA50)水平在肺癌诊断中的应用价值。 方法回顾性分析泰安市中心医院肿瘤科2012年1月至2013年12月收治的肺癌患者233例(研究组),其中非小细胞肺癌181例(腺癌129例,鳞癌52例),小细胞癌47例,其他类型5例;同期30例肺良性病变患者作为对照组。电化学发光法检测患者血清CYFRA21-1、CA125和CA50水平,比较3种标志物在肺癌不同病理类型患者中的水平以及联合检测对肺腺癌诊断和TNM分期的诊断价值,Kaplan-Meier生存曲线分析血清中3项标志物单项阳性和多项阳性的肺腺癌患者的生存时间。 结果腺癌组血清CA125和CA50[(125.06±42.98)U/mL,(17.43±8.51)U/mL]水平明显高于鳞癌组[(65.06±39.03)U/mL,(11.28±9.01)U/mL]和小细胞癌组[(70.32±49.88)U/mL,(7.43±6.07)U/mL](腺癌与鳞癌比较,CA125：q＝18.21,P＝0.01,CA50：q＝3.98,P＝0.05;腺癌与小细胞癌比较,CA125：q＝16.64,P＝0.03,CA50：q＝5.98,P＝0.03),腺癌组血清CYFRA21-1水平[(12.28±7.08)μg/L]高于小细胞癌组[(7.07±6.23)μg/L](q＝5.12,P＝0.03);腺癌TNM分期中,Ⅰ期患者的CYFRA21-1、CA125水平[(9.12±8.09)μg/L,(35.23±18.77)U/mL]明显低于Ⅳ期患者[(48.40±13.61)μg/L,(179.36±33.19)U/mL](CYFRA21-1：q＝8.28,P＝0.02;CA125：q＝31.21,P＝0.00);3项标志物联合检测敏感度为89.97%,特异度为85.09%;3项标志物单项阳性患者的生存时间长于多项阳性的肺腺癌患者(χ²＝2.91,P<0.01)。 结论血清CYFRA21-1、CA125和CA50水平检测在肺癌诊断、分期和预后中具有重要作用。     

Diagnostic value of elevated serum carbohydrate antigen 125 level in sarcoidosis

BACKGROUNDSarcoidosis is a multisystem disorder with unknown etiology, and it predominantly affects the lungs and intrathoracic lymph nodes. For patients with atypical clinical manifestations, the diagnosis of sarcoidosis is difficult and specific biomarkers may play an important role in assisting diagnosis. Previous research has demonstrated a correlation between sarcoidosis and increased carbohydrate antigen 125 (CA125), but remains a lack of large cohort studies to validate this observation. AIMTo compare serum CA125 levels in sarcoidosis patients and healthy controls, and explore whether CA125 can be used as a biomarker for the diagnosis of sarcoidosis.METHODSIn this study, the serum CA125 levels were measured by enzyme-linked immunosorbent assay in 108 consecutive sarcoidosis patients between June 2016 and December 2020 (31 males, 77 females; age at diagnosis 49.69 ± 9.10 years) and 112 healthy subjects. Data on the C-reactive protein, erythrocyte sedimentation rate, and angiotensin-converting enzyme were also collected. The association of serum CA125 levels with clinical, radiological, and respiratory functional characteristics was analyzed between patient groups with CA125 ≤ 35 U/mL or CA125 > 35 U/mL.RESULTSWe found that serum CA125 levels were higher in sarcoidosis patients compared to healthy controls (median: 44.78 vs 19.11 U/mL, P < 0.001). The area under the receiver operator characteristic was 0.9833 (95%CI: 0.9717-0.9949), and the best cutoff point was 32.33 U/mL. The elevated serum CA125 was notably associated with the percentage of predicted forced vital capacity (FVC%) and neutrophil-to-lymphocyte ratio (P = 0.043 and P = 0.038, respectively) in sarcoidosis patients. Multivariate analysis revealed that FVC% was a statistically notable predictor of elevated serum CA125 (P = 0.029). Also, our research revealed that compared to patients with Stage I of radiology classification, patients with Stage II and III showed a higher concentration of serum CA125 (46.16 ± 8.32 vs 41.00 ± 6.04 U/mL, P = 0.005, and 47.92 ± 10.10 vs 41.00 ± 6.04 U/mL, P = 0.002, respectively). CONCLUSIONSerum CA125 was highly increased in sarcoidosis patients and showed high efficiency for noninvasive diagnosis of the disease. In addition, abnormally elevated serum CA125 was correlated with pulmonary function and radiological Scadding’s classification of sarcoidosis.     

CA125、CA153联合检测对诊断子宫内膜癌的意义

目的探讨CA125、CA153联合检测对诊断子宫内膜癌的临床意义。方法36例经病理检查证实为子宫内膜癌的患者于入院时和手术后2~3个月进行CA125、CA153联合检测,以同期住院行剖腹手术、经病理证实为子宫肌瘤患者57例作为对照组。结果两项指标同时检测较单项检测对辅助诊断子宫内膜癌的敏感性提高到82.3%,虽特异性有所下降,但总的准确性提高到75.1%,与子宫肌瘤对照组比较,有统计学意义(P<0.05)。结论两项肿瘤标志物联合检测,相互补充,对鉴别子宫良、恶性疾病和判断预后及复发有重大的诊断意义。     

子宫内膜异位症患者血清CA125及CA19-9联合测定的临床评价

目的探讨血清CA125、CA19-9单独及联合测定对子宫内膜异位症(内异症)的诊断价值。方法测定内异症患者103例,子宫腺肌症组27例,子宫肌瘤41例及卵巢浆液性囊腺瘤25例血清CA19-9和CA125。结果内异症、子宫腺肌症、子宫肌瘤、卵巢浆液性囊腺瘤血清CA125阳性率分别为53.4%,57.7%,7.3%和16.0%。内异症、子宫腺肌症、子宫肌瘤CA19-9阳性率分别为48.5%,15.4%,5.7%。本组内异症Ⅰ+Ⅱ及Ⅲ+Ⅳ期患者CA125阳性率分别为34.8%及68.4%,CA19-9阳性率分别为32.6%及61.4%。内异症CA125测定的敏感性、特异性分别为53.4%、96.1%,CA19-9测定的敏感性,特异性分别为48.5%、92.1%,CA125诊断敏感性高于CA19-9,但差异无显著性(P>0.05)。子宫腺肌症CA125及CA19-9的敏感性分别为57.7%和15.4%,有显著性差异(P<0.05)。联合测定的阳性率71.8%,明显高于单独CA125及CA19-9测定阳性率(P<0.05)。结论血清CA125及CA19-9在内异症患者中均明显升高,二者联合测定可进一步提高诊断的敏感性。     

血清CA153、CA125和CEA联合检测在乳腺癌诊断中的应用

Objective To study the clinical singificance of serum tumor markers (CA153, CA125 and CEA) in doagnosis of breast cancer. Methods Electrochemiluminescence immunoassay (ECLIA) was used to analyze serum levels of CA153,CA125 and CEA in 55 patients with breast canc-er (breast cancer group),20 patients with benign breast lesions (benign breast lesion group) and 20 healthy controls (healthy control group). Results The levels of CA153, CA125 and CEA in breast cancer group were significantly higher than those in healthy control group (P<0.05); the levels of CEA and CA153 in breast cancer group were significantly higher than those in benign breast lesion group (P<0.05);the level of CA153 in postoperative patients was statistically lower than that in pre-operative patients (P<0.05);the levels of CEA and CA153 in breast cancer patients with stage Ⅲ and Ⅳ were significantly higher than those in healthy controls (P<0.05); the level of CA153 with stage Ⅲ and Ⅳ was higher than that in ones with stage Ⅰ and Ⅱ. The combined dection of CA153, CA125 and CEA in breast cancer patients increased the experimental sensitivity to 53.8% and specific-ity to 83.3%. Conclusion Detections of CA153,CA125 and CEA contribute to diagnosis of breast cancer. CA153 and CEA are of clinical practical value in differential diagnosis of benign and malignant breast tumor,monitoring of course of breast cancer.     

血清CEA、CA-199和CA-125检测在原发性肝细胞癌诊断中的临床价值

目的探讨血清癌胚抗原(CEA)、糖类抗原199(CA-199)和糖类抗原125(CA-125)联合检测对原发性肝细胞癌(PHC)的诊断价值。方法回顾性分析2011年1月至2014年1月就诊的的PHC患者86例及其相关临床资料,同时以良性肝病(包括肝血管瘤、肝囊肿等)患者35例和普通门诊体检健康者48例作为该实验的对照组。结果 PHC组患者血清诊断肿瘤标志物CEA、CA-199以及CA-125的测定值相对于良性肝病组患者和正常对照组显著升高(P0.05)。三种血清诊断肿瘤标志物进行联合检测相对于单独检测能够显著提高PHC组患者的阳性诊断率(P0.05)。当PHC组患者血清诊断肿瘤标志物CEA、CA-199以及CA-125分别进行独检时其敏感度是67.5%、27.5%和42.5%,而三种标志物联检其敏感度可提高至95%。结论联合进行血清CEA、CA-199和CA-125检测能够显著提高诊断原发性肝细胞癌的敏感度。     

超声在早期卵巢癌诊断中的价值

目的　探讨超声在早期卵巢癌诊断中的价值。方法　分析经超声、肿瘤标记物CA12 5检查 ,并经手术及病理证实的早期卵巢癌患者 47例。结果　肿瘤呈囊性 2 9例 ,内有乳头或实性成分 ,单房 5例 ,多房 2 4例 ;囊实性 13例 ;实性 5例。超声发现卵巢病变 46例 ,诊断卵巢恶性病变 42例。术前超声诊断的敏感性、特异性、阳性预测值和阴性预测值分别为 89.4%、92 .7%、43 .8%和 99.3 %。 47例早期卵巢癌患者中 ,CA12 5 >3 5U /ml者 2 4例 ,敏感性、特异性、阳性预测值和阴性预测值分别为 5 1.1%、90 .2 %、2 5 .0 %和 96.7%。超声对早期卵巢癌的敏感性较血清CA12 5高 (P <0 .0 1)。结论　超声在早期卵巢癌诊断中起着重要的作用 ,为早期卵巢癌的首选检查方法。